相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Parvathi Sudha et al.
CLINICAL CANCER RESEARCH (2022)
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Sarah Gooding et al.
BLOOD (2021)
Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
Matteo Costacurta et al.
HAEMATOLOGICA (2021)
Cereblon enhancer methylation and IMiD resistance in multiple myeloma
Larissa Haertle et al.
BLOOD (2021)
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Anjan Thakurta et al.
Oncotarget (2021)
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM
Marietta S. Truger et al.
BLOOD ADVANCES (2021)
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
Shumpei Tateno et al.
SCIENTIFIC REPORTS (2020)
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
Bachisio Ziccheddu et al.
BLOOD ADVANCES (2020)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
Jiye Liu et al.
LEUKEMIA (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma
Ajinkya Patil et al.
BLOOD ADVANCES (2019)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity
Quinlan L. Sievers et al.
BLOOD (2018)
UBE2G1 governs the destruction of cereblon neomorphic substrates
Gang Lu et al.
ELIFE (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Targeted inhibition of the COP9 signalosome for treatment of cancer
Anita Schlierf et al.
NATURE COMMUNICATIONS (2016)
Crystal structure of the human COP9 signalosome
Gondichatnahalli M. Lingaraju et al.
NATURE (2014)
分享论文
